Progen gets strategic advice
Wednesday, 27 August, 2008
Progen Pharmaceuticals [ASX: PGL] has appointed a new group of corporate advisors to help guide the company's development.
The company has commissioned the services of the independent corporate advisory firm Beerworth and Partners (BPL).
BPL has been hired to assess Progen's operations and develop strategic options to be reviewed by Progen's Board of directors.
The advisory firm will also provide general corporate advice and assist the board as required.
According to Progen, the decision to hire advisors was made when the directors realised the company's strong cash position after terminating the PI88 Phase III Pathway study in liver cancer.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
